Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

January 29, 2018January 29, 2018

Asthma Drug Montelukast Tested as Alzheimer’s Treatment in Proof-of-concept Trial

News

Canada’s IntelGenx has launched a Phase 2a proof-of-concept trial to explore whether the old asthma medication montelukast may be an option for treating Alzheimer’s disease. The idea that montelukast — also ... Read more

January 24, 2018

Alzheimer’s-Linked Gene Behaves as Virus, Scientists Find in Odd Discovery

News

Two research teams have independently discovered that a cognition-related gene behaves like a virus in the nervous system — passing on its genetic material between neurons. While scientists are still working ... Read more

January 22, 2018January 22, 2018

Saving Brain Connections by Targeting Synaptic Proteins May Treat Alzheimer’s, Study Finds

News

Proteins in nerve cell synapses, which transmit signals between neurons, are abnormal in the brains of patients with Alzheimer’s disease and other dementias, Swedish researchers concluded after performing a large-scale ... Read more

January 15, 2018January 15, 2018

DrugPredict Wins $2.8M NIH Grant to Repurpose Approved Therapies to Treat Alzheimer’s

News

A group of U.S. researchers hoping to identify already approved medications to repurpose as Alzheimer’s disease treatments has won a $2.8 million, five-year grant from the National Institute on Aging, a ... Read more

January 12, 2018

Researchers Abandon Idalopirdine as Alzheimer’s Treatment After Phase 3 Failures

News

Another treatment has joined the long list of compounds that have failed to show effectiveness against Alzheimer’s disease. Three Phase 3 clinical trials showed that idalopirdine was unable to improve ... Read more

January 3, 2018

Top 10 Alzheimer’s Disease Stories of 2017

News

With 2017 behind us, Alzheimer’s News Today looks forward to bringing our readers news and updates on Alzheimer’s disease research discoveries, treatment developments, clinical trials, and events in the year ... Read more

November 29, 2017

Standard Alzheimer’s Treatments Seen to Prevent Effects of TauRx’s Tau Inhibitor

News

TauRx Therapeutics’ experimental Alzheimer’s disease treatment LMTX may slow cognitive decline in patients at doses as low as 4 mg — but only when used without other Alzheimer’s drugs — a ... Read more

November 28, 2017November 28, 2017

Anavex Highlights Role of Sigma-1 Brain Receptor in Alzheimer’s Development

News

Anavex Life Sciences has published a study demonstrating the sigma-1 receptor’s role in Alzheimer’s disease. The data contained in it supports the New York-based company’s development of compounds stimulating this ... Read more

November 15, 2017

Bill Gates Joins Efforts to Develop New Therapy Strategies for Alzheimer’s Disease

News

Billionaire Bill Gates is joining efforts to develop new treatments for Alzheimer’s disease. Gates made the announcement in a recent blog post in which he outlined five areas where more ... Read more

November 8, 2017November 8, 2017

Anavex ‘Cautiously Optimistic’ After Noting Cognitive Improvement in Alzheimer’s Treatment

News

Anavex Life Sciences says its Alzheimer’s drug candidate Anavex 2-73 may have a role in treating the disease. Data from a long-term extension trial, although small, indicated that the therapy improved ... Read more